Neuroprotection in Acute Ischemic Stroke "H2M"

Active, not recruiting

Phase 2/3 Results N/A

Summary of Purpose

This is a pilot randomized control trial (RCT) to explore the possible beneficial effect of a novel combination therapy consisting of molecular hydrogen H2 plus minocycline ("H2M"), on neurological recovery after acute ischemic stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 24 October 2017.

2 Aug 2017 20 Oct 2017 2 Aug 2019 2 Nov 2019 1 Oct 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

Not available

Contacts

Not available